{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:00:09Z","timestamp":1783702809394,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.gastrohep.2020.04.012","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T17:55:21Z","timestamp":1597946121000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Farmacolog\u00eda y seguridad de tofacitinib en colitis ulcerosa"],"prefix":"10.1016","volume":"44","author":[{"given":"Antonio","family":"L\u00f3pez-Sanrom\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan V.","family":"Esplugues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2020.04.012_bib0260","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/gutjnl-2012-302311","article-title":"Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study","volume":"62","author":"Hoivik","year":"2013","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0265","doi-asserted-by":"crossref","first-page":"S516","DOI":"10.1093\/ecco-jcc\/jjy222.914","article-title":"Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU","volume":"13","author":"Chaparro","year":"2019","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0270","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.gastrohep.2017.11.007","article-title":"Recomendaciones del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal","volume":"41","author":"Bermejo","year":"2018","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0275","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3748\/wjg.v20.i12.3146","article-title":"Immunosuppressive therapies for inflammatory bowel disease","volume":"20","author":"Zenlea","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0280","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/14740338.2017.1298743","article-title":"The safety of biological pharmacotherapy for the treatment of ulcerative colitis","volume":"16","author":"Fiorino","year":"2017","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0285","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/14656566.2016.1187132","article-title":"Maintenance therapy options for ulcerative colitis","volume":"17","author":"Chaparro","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0290","first-page":"606","article-title":"Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the Eneida Registry","volume":"26","author":"Casanova","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0295","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0300","unstructured":"Food and Drug Administration. Xeljanz full prescribing information [consultado 18 Mar 2019]. Disponible en: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0305","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de tofacitinib (Xeljanz\u00ae) [consultado 11 Feb 2020]. Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200131146843\/anx_146843_es.pdf"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0310","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0315","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0320","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of Janus Kinase inhibitors in inflammatory bowel disease","volume":"11","author":"De Vries","year":"2017","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0325","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.pharep.2016.04.001","article-title":"Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes","volume":"68","author":"Galien","year":"2016","journal-title":"Pharmacol Rep."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0330","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0335","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1381612825666190405141410","article-title":"JAK Inhibition: The most promising agents in the IBD pipeline?","volume":"25","author":"Fernandez-Clotet","year":"2019","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0340","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0345","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/jm801142b","article-title":"Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-y l)-3-oxopropanenitrile (CP-690,550)","volume":"51","author":"Jiang","year":"2008","journal-title":"J Med Chem."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0350","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0355","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0360","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0091270008330982","article-title":"Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers","volume":"49","author":"Lawendy","year":"2009","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40262-018-0676-z","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis","volume":"58","author":"Berends","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0370","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0375","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ordas","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0380","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2020.04.012_bib0385","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1093\/ecco-jcc\/jjy222.590","article-title":"Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials","volume":"13","author":"Sandborn","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0390","unstructured":"Winthrop KL, Loftus Jr EV, Baumgart DC, Salese L, Thorpe AJ, Lawendy N, et al,. Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates in the Tofacitinib Ulcerative Colitis Clinical Programme. United European Gastroenterol J. 2019 [consultado 6 Nov 2019];7:OP007. Disponible en: https:\/\/ueg-elearning.s3-eu-west-1.amazonaws.com\/ueg-week-2019\/UEGWeek_Abstracts_2019.pdf"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0395","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/apt.14449","article-title":"Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis","volume":"47","author":"Bonovas","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0400","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s11096-018-0743-4","article-title":"Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis","volume":"40","author":"Trigo-Vicente","year":"2018","journal-title":"Int J Clin Pharm."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0405","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0410","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.14309\/01.ajg.0000578208.09449.08","article-title":"Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical program (P034)","volume":"114","author":"Gary","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0415","unstructured":"European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots [consultado 16 Nov 2019]. Disponible en: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0420","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0425","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0430","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0435","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0440","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/1744666X.2017.1343668","article-title":"New treatment strategies for ulcerative colitis","volume":"13","author":"Panes","year":"2017","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0445","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0450","unstructured":"GETECCU. Vacunas y algoritmos de actuaci\u00f3n en pacientes con Enfermedad Inflamatoria Intestinal; 2018 [consultado 14 Jun 2019]. Disponible en: https:\/\/www.educainflamatoria.com\/images\/2018\/Folleto%20Vacunas%20nuevo%207.pdf"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0455","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.cgh.2018.12.044","article-title":"Tofacitinib: A Jak of All Trades","volume":"17","author":"Burke","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0460","doi-asserted-by":"crossref","first-page":"S048","DOI":"10.1093\/ecco-jcc\/jjx180.062","article-title":"Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme","volume":"12","author":"Lichtenstein","year":"2018","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0465","unstructured":"Lichtenstein GR, Ciorba MA, Rogler G, Quirk D, Pedersen RD, Lawendy N, et al. Tofacitinib for the treatment of ulcerative colitis: an update on the analysis of malignancy rates from the UC clinical programme. United European Gastroenterol J. 2019 [consultado 6 Nov 2019];7:P0393. Disponible en: https:\/\/ueg-elearning.s3-eu-west-1.amazonaws.com\/ueg-week-2019\/UEGWeek_Abstracts_2019.pdf"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0470","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0475","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1076029616632906","article-title":"Etiopathogenesis prevention, and treatment of thromboembolism in inflammatory bowel disease","volume":"23","author":"Alkim","year":"2017","journal-title":"Clin Appl Thromb Hemost."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0480","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0485","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Tofacitinib (?Xeljanz): nuevas restricciones de uso [consultado 6 Nov 2019]. Disponible en: https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/tofacitinib-xeljanz-nuevas-restricciones-de-uso\/"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0490","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1093\/ecco-jcc\/jjy222.603","article-title":"Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies","volume":"13","author":"Lichtenstein","year":"2019","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0495","doi-asserted-by":"crossref","unstructured":"Melmed GY, Chang S, Kulisek N, Fan H, Lawendy N, Maller E, et al. Laboratory parameters related to monitoring in patients with ulcerative colitis treated with tofacitinib for up to 3 years in the OCTAVE open-label, long-term extension study. United European Gastroenterol J. 2019 [consultado 6 Nov 2019];7:P0390. Disponible en: https:\/\/ueg-elearning.s3-eu-west-1.amazonaws.com\/ueg-week-2019\/UEGWeek_Abstracts_2019.pdf","DOI":"10.14309\/01.ajg.0000592464.96938.73"},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0500","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0505","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the RA clinical development program","volume":"70","author":"Cohen","year":"2018","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.gastrohep.2020.04.012_bib0510","unstructured":"Pfizer. Pfizer announces CHMP opinion for XELJANZ\u00ae (tofacitinib) in the European Union related to ongoing review of the product [consultado 16 Nov 2019]. Disponible en: https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2019\/Pfizer-Announces-CHMP-Opinion-for-XELJANZ-tofacitinib-in-the-European-Union-Related-to-Ongoing-Review-of-the-Product-\/default.aspx"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570520302363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570520302363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:45:38Z","timestamp":1759322738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570520302363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0210570520302363"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.04.012","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farmacolog\u00eda y seguridad de tofacitinib en colitis ulcerosa","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}